Genetic or pharmacological downregulation of C/EBPα activity results in enhanced sensitivity of AML cells to FLT3i, highlighting C/EBPα activation as a targetable PR mechanism and supporting clinical studies evaluating combination therapy of FLT3i and C/EBPα inactivation as a next-generation AML treatment strategy. This evidence concerns the gene CEBPA and acute myeloid leukemia.